Advisory Committee on Immunization Practices, 58277-58278 [2023-18288]

Download as PDF Federal Register / Vol. 88, No. 164 / Friday, August 25, 2023 / Notices DEPARTMENT OF DEFENSE SUPPLEMENTARY INFORMATION: D. Annual Burden GENERAL SERVICES ADMINISTRATION A. OMB Control Number, Title, and Any Associated Form(s) NATIONAL AERONAUTICS AND SPACE ADMINISTRATION 9000–0011, Preaward Survey Forms (Standard Forms 1403, 1404, 1405, 1406, 1407, and 1408). General Services Administration Respondents: 168. Total Annual Responses: 168. Total Burden Hours: 4,032. [OMB Control No. 9000–0011; Docket No. 2023–0053; Sequence No. 4] B. Need and Uses Submission for OMB Review; Preaward Survey Forms (Standard Forms 1403, 1404, 1405, 1406, 1407, and 1408) Department of Defense (DOD), General Services Administration (GSA), and National Aeronautics and Space Administration (NASA). ACTION: Notice. AGENCY: Under the provisions of the Paperwork Reduction Act, the Regulatory Secretariat Division has submitted to the Office of Management and Budget (OMB) a request to review and approve an extension of a previously approved information collection requirement regarding preaward survey forms. DATES: Submit comments on or before September 25, 2023. ADDRESSES: Written comments and recommendations for this information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting ‘‘Currently under Review—Open for Public Comments’’ or by using the search function. Additionally, submit a copy to GSA through https://www.regulations.gov and follow the instructions on the site. This website provides the ability to type short comments directly into the comment field or attach a file for lengthier comments. Instructions: All items submitted must cite OMB Control No. 9000–0011, Preaward Survey Forms (Standard Forms 1403, 1404, 1405, 1406, 1407, and 1408). Comments received generally will be posted without change to https://www.regulations.gov, including any personal and/or business confidential information provided. To confirm receipt of your comment(s), please check www.regulations.gov, approximately two-to-three days after submission to verify posting. If there are difficulties submitting comments, contact the GSA Regulatory Secretariat Division at 202–501–4755 or GSARegSec@gsa.gov. FOR FURTHER INFORMATION CONTACT: Zenaida Delgado, Procurement Analyst, at telephone 202–969–7207, or zenaida.delgado@gsa.gov. ddrumheller on DSK120RN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 18:23 Aug 24, 2023 Jkt 259001 Contracting officers, prior to award, must make an affirmative determination that the prospective contractor is responsible, i.e., capable of performing the contract. Before making such a determination, the contracting officer must have or obtain sufficient information to establish that the prospective contractor: has adequate financial resources; or the ability to obtain such resources; is able to comply with required delivery schedule; has a satisfactory record of performance; has a satisfactory record of integrity; and is otherwise qualified and eligible to receive an award under appropriate laws and regulations. If such information is not readily available to the contracting officer, it is obtained through a preaward survey conducted by the contract administration office or another organization designated by the agency to conduct the surveys. The necessary data is collected from available data or through plant visits, phone calls, and correspondence in detail commensurate with the dollar value and complexity of the procurement. This clearance covers the information that prospective contractors must provide to ensure proper completion of the following preaward survey forms prescribed by the Federal Acquisition Regulation (FAR): • Standard Form 1403 Preaward Survey of Prospective Contractor (General) • Standard Form 1404 Preaward Survey of Prospective Contractor (Technical) • Standard Form 1405 Preaward Survey of Prospective Contractor (Production) • Standard Form 1406 Preaward Survey of Prospective Contractor (Quality Assurance) • Standard Form 1407 Preaward Survey of Prospective Contractor (Financial Capability) • Standard Form 1408 Preaward Survey of Prospective Contractor (Accounting System) C. Common Form The General Services Administration is the sponsor agency of this common form. All executive agencies covered by the FAR will use this common form. Each executive agency will report their agency burden separately, and the reported information will be available at Reginfo.gov. PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 58277 E. Public Comment A 60-day notice was published in the Federal Register at 88 FR 39849, on June 20, 2023. No comments were received. Obtaining Copies: Requesters may obtain a copy of the information collection documents from the GSA Regulatory Secretariat Division by calling 202–501–4755 or emailing GSARegSec@gsa.gov. Please cite OMB Control No. 9000–0011, Preaward Survey Forms (Standard Forms 1403, 1404, 1405, 1406, 1407, and 1408). Janet Fry, Director, Federal Acquisition Policy Division, Office of Governmentwide Acquisition Policy, Office of Acquisition Policy, Office of Governmentwide Policy. [FR Doc. 2023–18352 Filed 8–24–23; 8:45 am] BILLING CODE 6820–EP–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket No. CDC–2023–0060] Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice and request for comment. AGENCY: In accordance with regulatory provisions, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. Time will be available for public comment. DATES: The meeting will be held on September 12, 2023, 10 a.m. to 4 p.m., EDT (date and times subject to change; see the ACIP website for updates: https://www.cdc.gov/vaccines/acip/ index.htm). Written comments will be received between August 25–September 8, 2023. ADDRESSES: You may submit comments, identified by Docket No. CDC–2023– 0060, by either of the methods listed below. CDC does not accept comments by email. • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. SUMMARY: E:\FR\FM\25AUN1.SGM 25AUN1 ddrumheller on DSK120RN23PROD with NOTICES1 58278 Federal Register / Vol. 88, No. 164 / Friday, August 25, 2023 / Notices • Mail: Ms. Stephanie Thomas, ACIP Meeting, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–8, Atlanta, Georgia 30329–4027. Attn: Docket No. CDC– 2023–0060. Instructions: All submissions received must include the Agency name and docket number. All relevant comments received in conformance with the https://www.regulations.gov suitability policy will be posted without change to https://www.regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to https://www.regulations.gov. The meeting will be webcast live via the World Wide Web. The webcast link can be found on the ACIP website at https://www.cdc.gov/vaccines/acip/ index.html. FOR FURTHER INFORMATION CONTACT: Ms. Stephanie Thomas, Committee Management Specialist, Advisory Committee on Immunization Practices, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–8, Atlanta, Georgia 30329–4027. Telephone: (404) 639–8836; Email: ACIP@cdc.gov. SUPPLEMENTARY INFORMATION: Purpose: The Advisory Committee on Immunization Practices (ACIP) is charged with advising the Director, Centers for Disease Control and Prevention (CDC), on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines For Children program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under applicable provisions of the Affordable Care Act and section 2713 of the Public Health Service Act, immunization recommendations of ACIP that have been approved by the Director, CDC, and appear on CDC immunization schedules generally must be covered by applicable health plans. Matters To Be Considered: The agenda will include discussion of COVID–19 vaccines. Recommendation votes for COVID–19 vaccines are scheduled. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda, visit https:// www.cdc.gov/vaccines/acip/meetings/ index.html. Meeting Information: The meeting will be webcast live via the World Wide VerDate Sep<11>2014 18:23 Aug 24, 2023 Jkt 259001 Web. For more information on ACIP, please visit the ACIP website: https:// www.cdc.gov/vaccines/acip/. Public Participation Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/ near-duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket. Written Public Comment: The docket will be opened to receive written comments on August 25, 2023. Written comments must be received by September 8, 2023. Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below. Procedure for Oral Public Comment: All persons interested in making an oral public comment at the September 12, 2023, ACIP meeting must submit a request at https://www.cdc.gov/ vaccines/acip/meetings/ no later than 11:59 p.m., EDT, September 8, 2023, according to the instructions provided. If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email on September 11, 2023. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to three minutes, and each speaker may only speak once per meeting. PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2023–18288 Filed 8–24–23; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [60–Day–23–23HS; Docket No. CDC–2023– 0074] Proposed Data Collection Submitted for Public Comment and Recommendations Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice with comment period. AGENCY: The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Program Evaluation for PS22– 2208 Component 2. This information collection request is designed to monitor and evaluate the PS22–2208 Component 2 funding opportunity’s overall goal of supporting syringe services program (SSP) subrecipients in meeting the needs of people who use drugs (PWUD) and reducing infectious disease and other harms related to drug use during the 5-year PS22–2208 Cooperative Agreement. DATES: CDC must receive written comments on or before October 24, 2023. SUMMARY: You may submit comments, identified by Docket No. CDC–2023– 0074 by either of the following methods: ADDRESSES: E:\FR\FM\25AUN1.SGM 25AUN1

Agencies

[Federal Register Volume 88, Number 164 (Friday, August 25, 2023)]
[Notices]
[Pages 58277-58278]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-18288]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2023-0060]


Advisory Committee on Immunization Practices

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice and request for comment.

-----------------------------------------------------------------------

SUMMARY: In accordance with regulatory provisions, the Centers for 
Disease Control and Prevention (CDC) announces the following meeting of 
the Advisory Committee on Immunization Practices (ACIP). This meeting 
is open to the public. Time will be available for public comment.

DATES: The meeting will be held on September 12, 2023, 10 a.m. to 4 
p.m., EDT (date and times subject to change; see the ACIP website for 
updates: https://www.cdc.gov/vaccines/acip/index.htm).
    Written comments will be received between August 25-September 8, 
2023.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2023-
0060, by either of the methods listed below. CDC does not accept 
comments by email.
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments.

[[Page 58278]]

     Mail: Ms. Stephanie Thomas, ACIP Meeting, Centers for 
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, 
Atlanta, Georgia 30329-4027. Attn: Docket No. CDC-2023-0060.
    Instructions: All submissions received must include the Agency name 
and docket number. All relevant comments received in conformance with 
the https://www.regulations.gov suitability policy will be posted 
without change to https://www.regulations.gov, including any personal 
information provided. For access to the docket to read background 
documents or comments received, go to https://www.regulations.gov.
    The meeting will be webcast live via the World Wide Web. The 
webcast link can be found on the ACIP website at https://www.cdc.gov/vaccines/acip/.

FOR FURTHER INFORMATION CONTACT: Ms. Stephanie Thomas, Committee 
Management Specialist, Advisory Committee on Immunization Practices, 
National Center for Immunization and Respiratory Diseases, Centers for 
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, 
Atlanta, Georgia 30329-4027. Telephone: (404) 639-8836; Email: 
[email protected].

SUPPLEMENTARY INFORMATION: 
    Purpose: The Advisory Committee on Immunization Practices (ACIP) is 
charged with advising the Director, Centers for Disease Control and 
Prevention (CDC), on the use of immunizing agents. In addition, under 
42 U.S.C. 1396s, the Committee is mandated to establish and 
periodically review and, as appropriate, revise the list of vaccines 
for administration to vaccine-eligible children through the Vaccines 
For Children program, along with schedules regarding dosing interval, 
dosage, and contraindications to administration of vaccines. Further, 
under applicable provisions of the Affordable Care Act and section 2713 
of the Public Health Service Act, immunization recommendations of ACIP 
that have been approved by the Director, CDC, and appear on CDC 
immunization schedules generally must be covered by applicable health 
plans.
    Matters To Be Considered: The agenda will include discussion of 
COVID-19 vaccines. Recommendation votes for COVID-19 vaccines are 
scheduled. Agenda items are subject to change as priorities dictate. 
For more information on the meeting agenda, visit https://www.cdc.gov/vaccines/acip/meetings/.
    Meeting Information: The meeting will be webcast live via the World 
Wide Web. For more information on ACIP, please visit the ACIP website: 
https://www.cdc.gov/vaccines/acip/.

Public Participation

    Interested persons or organizations are invited to participate by 
submitting written views, recommendations, and data. Please note that 
comments received, including attachments and other supporting 
materials, are part of the public record and are subject to public 
disclosure. Comments will be posted on https://www.regulations.gov. 
Therefore, do not include any information in your comment or supporting 
materials that you consider confidential or inappropriate for public 
disclosure. If you include your name, contact information, or other 
information that identifies you in the body of your comments, that 
information will be on public display. CDC will review all submissions 
and may choose to redact, or withhold, submissions containing private 
or proprietary information such as Social Security numbers, medical 
information, inappropriate language, or duplicate/near-duplicate 
examples of a mass-mail campaign. CDC will carefully consider all 
comments submitted into the docket.
    Written Public Comment: The docket will be opened to receive 
written comments on August 25, 2023. Written comments must be received 
by September 8, 2023.
    Oral Public Comment: This meeting will include time for members of 
the public to make an oral comment. Priority will be given to 
individuals who submit a request to make an oral public comment before 
the meeting according to the procedures below.
    Procedure for Oral Public Comment: All persons interested in making 
an oral public comment at the September 12, 2023, ACIP meeting must 
submit a request at https://www.cdc.gov/vaccines/acip/meetings/ no later than 11:59 p.m., EDT, September 8, 2023, according 
to the instructions provided.
    If the number of persons requesting to speak is greater than can be 
reasonably accommodated during the scheduled time, CDC will conduct a 
lottery to determine the speakers for the scheduled public comment 
session. CDC staff will notify individuals regarding their request to 
speak by email on September 11, 2023. To accommodate the significant 
interest in participation in the oral public comment session of ACIP 
meetings, each speaker will be limited to three minutes, and each 
speaker may only speak once per meeting.
    The Director, Office of Strategic Business Initiatives, Office of 
the Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other committee 
management activities, for both the Centers for Disease Control and 
Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-18288 Filed 8-24-23; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.